文献速递腹部技术与安全US

前瞻性多中心评估美国肝病研究学会2023版指南下的肝细胞癌监测

Prospective Multicenter Evaluation of Hepatocellular Carcinoma Surveillance under American Association for the Study of Liver Diseases Version 2023 Guidance.
PubMed 文献 · Radiology · 2026-01-01

本研究前瞻性连续纳入三个中心953例高危受试者,评估AASLD v2023对肝细胞癌的监测效能,并与US LI-RADS v2017和AASLD v2018比较。AASLD v2023整合算法敏感度94%、阴性预测值99.6%,优于v2017和v2018,但特异度较低(84%)。

要点

  • AASLD v2023整合算法对肝细胞癌检测敏感度94%、阴性预测值99.6%,优于US LI-RADS v2017和AASLD v2018。
  • 新监测触发项(VIS-C、AFP升高、病灶增长)单项敏感度8%–48%,特异度94%–99.4%。
  • AASLD v2023特异度84%,低于US LI-RADS v2017的90%和AASLD v2018的89%。

核心结论

  • AASLD v2023提高了肝细胞癌监测的敏感度和阴性预测值,优于US LI-RADS v2017和AASLD v2018。

研究设计与样本

  • 前瞻性研究,2023年7月至2024年10月连续纳入三个中心953例高危受试者,均接受超声和AFP监测。

诊断标准与关键数值

  • AASLD v2023整合算法敏感度94%(47/50)、阴性预测值99.6%(758/761)、特异度84%(758/903);US LI-RADS v2017敏感度60%(30/50)、阴性预测值98%(814/834)、特异度90%(814/903);AASLD v2018敏感度76%(38/50)、阴性预测值98.5%(805/817)、特异度89%(805/903)。

临床应用与阅片要点

  • AASLD v2023整合算法较US LI-RADS v2017和AASLD v2018提高了肝细胞癌监测敏感度和阴性预测值,但特异度较低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background The 2023 update of the American Association for the Study of Liver Diseases (AASLD version 2023 [hereafter, v2023]) guidance introduced new triggers for hepatocellular carcinoma (HCC) surveillance, incorporating US visualization score, increasing α-fetoprotein (AFP) level, and lesion growth, but has not yet been validated. Purpose To assess the surveillance performance of AASLD v2023 for HCC detection in comparison to Liver Imaging Reporting and Data System (LI-RADS) version 2017 (hereafter, v2017) and AASLD version 2018 (hereafter, v2018) in participants at high risk of HCC. Materials and Methods This prospective study consecutively enrolled high-risk participants undergoing US and AFP surveillance across three institutions between July 2023 and October 2024. Surveillance performance of US LI-RADS v2017, AASLD v2018, and AASLD v2023 for HCC detection was compared through sensitivity, specificity, positive predictive value, and negative predictive value (NPV). Multivariable logistic regression helped identify predictors of false-negative and false-positive classifications. Results Among 953 participants (median age, 51 years; IQR, 45-58 years; 658 men), 5% (50 of 953) had HCC. The new surveillance triggers (visualization score VIS-C, increasing AFP level, and lesion growth) demonstrated sensitivities ranging from 8% (four of 50 participants) to 48% (24 of 50 participants), with high specificities of 94% (849 of 903 participants) to 99.4% (898 of 903 participants). As an integrated algorithm, AASLD v2023 achieved a sensitivity of 94% (47 of 50 participants) and NPV of 99.6% (758 of 761 participants) for HCC detection, surpassing US LI-RADS v2017 (sensitivity, 60% [30 of 50 participants], P < .001; NPV, 98% [814 of 834 participants], P = .001) and AASLD v2018 (sensitivity, 76% [38 of 50 participants], P = .02; NPV, 98.5% [805 of 817 participants], P = .04). Specificity was lower than that with US LI-RADS v2017 (84% [758 of 903 participants] vs 90% [814 of 903 participants], P < .001) and AASLD v2018 (84% [758 of 903 participants] vs 89% [805 of 903 participants], P = .001). For early HCC, sensitivity remained superior to that of other algorithms (P < .001, P = .04). At multivariable analysis, AFP level of less than 20 ng/mL (odds ratio, 11.76; P < .001) and absence of cirrhosis (odds ratio, 2.45; P = .03) were independently associated with false-positive findings for AASLD v2023. Conclusion AASLD v2023 improved the sensitivity and NPV for HCC surveillance, outperforming US LI-RADS v2017 and AASLD v2018. Chinese Clinical Trial Registry no. ChiCTR2100054330 © RSNA, 2026 Supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Cheng MQ, Hu HT, Wu SH, et al. Prospective Multicenter Evaluation of Hepatocellular Carcinoma Surveillance under American Association for the Study of Liver Diseases Version 2023 Guidance. Radiology. 2026. PMID: 41557897. doi:10.1148/radiol.252252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。